Bristol-Myers Squibb is extending its partnership with Japan’s Otsuka Pharmaceuticals until 2015 on the US sales of their blockbuster psychiatric drug, Abilify® (aripiprazole). The agreement also included the opportunity for the two companies to work together on two oncology products, Sprycel® (dasatinib) and Ixempra® (ixabepilone).